DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on January 28, 2008; DOI: 10.1124/dmd.107.016824


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.016824v1
36/4/745    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Han, J.-F.
Right arrow Articles by Hong, J.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, J.-F.
Right arrow Articles by Hong, J.-Y.


Received for publication May 30, 2007.
Revised January 21, 2008.
Accepted for publication January 23, 2008.

Metabolism of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by Human CYP1B1 Genetic Variants

Jing-Fen Han 1, Xiao-Yang He 2, Jason S Herrington 2, Lori A White 3, Jun-Feng Zhang 4, Jun-Yan Hong 2*

1 SPH/EOHSI, UMDNJ 2 SPH/EOHSI/UMDNJ 3 Department of Biochemistry and Microbiology, Rutgers 4 SPH/EOHSI.UMDNJ

* Address correspondence to: E-mail: jyhong{at}eohsi.rutgers.edu

Abstract

Human cytochrome P450 1B1 (CYP1B1) plays a critical role in the metabolic activation of a variety of pro-carcinogens, including 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). The existence of human CYP1B1 missense genetic variants has been demonstrated but their activities in metabolizing PhIP are unknown. In this study, we expressed 15 naturally-occurring CYP1B1 variants (with either single or multiple amino acid substitutions) and determined their activity changes in metabolizing PhIP to its two major metabolites, 2-hydroxyamino-PhIP (N2-OH-PhIP) and 4'-hydroxy-PhIP (4'-OH-PhIP). While the PhIP-metabolizing activities of four variants (Ala119Ser, Pro379Leu, Ala443Gly, Arg48Gly/Leu432Val) were comparable to that of the expressed wild-type CYP1B1, five variants (Trp57Cys, Gly61Glu, Arg48Gly/Ala119Ser, Arg48Gly/Ala119Ser/ Leu432Val, Arg48Gly/ Ala119Ser/Leu432Val/Ala443Gly) exhibited more than two fold decrease in activity and a reduction in the catalytic efficiency (Vmax/Km) for both N- and 4-hydroxylation of PhIP. Six variants (Gly365Trp, Glu387Lys, Arg390His, Pro437Leu, Asn453Ser, Arg469Trp) showed little activity in PhIP metabolism but the molecular mechanisms involved are apparently different. The microsomal CYP1B1 protein level was significantly decreased for the Trp365, Lys387, and His390 variants and was not detectable for the Ser453 variant. In contrast, there was no difference between the Trp469 variant and the wild-type in the microsomal CYP1B1 protein level and P450 content but the Trp469 variant totally lost its metabolic activity towards PhIP. The Leu437 variant also had a substantial amount of CYP1B1 protein in the microsomes but lacked detectable P450 peak and activity. Our results should be useful in selecting appropriate CYP1B1 variants as cancer susceptibility biomarkers for human population studies related to PhIP exposure.


Key words: CYP expression, CYP1B, cytochrome P450 isoforms, gene/environment interactions, HPLC, human CYP enzymes, kinetics, microsomes





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.